Patents Examined by Xiaozhen Xie
  • Slit2D2-HSA fusion protein and use thereof against tumours
    Patent number: 11041157
    Abstract: Provided in the present invention are a Slit2D2-HAS fusion protein and the use thereof against tumours. The fusion protein can significantly inhibit the migration of tumour cells. Also provided in the present invention are a pharmaceutical composition comprising the fusion protein and a method for preparing the fusion protein.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: June 22, 2021
    Inventor: Huashun Li
  • Systems, compositions, and methods for transplantation
    Patent number: 11040092
    Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: June 22, 2021
    Assignee: CYTONICS CORPORATION
    Inventors: Lewis Hanna, John David Laughlin, Shawn Robert Browning
  • Methods and compositions for regenerating tissues
    Patent number: 11034741
    Abstract: Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 15, 2021
    Assignee: NellOne Therapeutics, Inc.
    Inventor: Cymbeline T. Culiat
  • Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
    Patent number: 11028139
    Abstract: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 8, 2021
    Assignee: NEXEL CO., LTD.
    Inventors: Choong Seong Han, Dong Hun Woo, Gun Sik Cho, Jeong Seong Kim, Geun Ho An, Hye Ryeon Jeon
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 11021528
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Pfizer Inc., Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Diagnosis, prevention and treatment of diseases of the joint
    Patent number: 10980860
    Abstract: The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: April 20, 2021
    Assignee: Ascendis Pharma A/S
    Inventors: Dirk Vetter, Ulrich Hersel, Kennett Sprogøe, Nora Kaluza, Oliver Keil, Guillaume Maitro, Harald Rau
  • Compounds, compositions and uses thereof for improvement of bone disorders
    Patent number: 10947285
    Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Amolyt Pharma
    Inventors: David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
  • Systems, compositions, and methods for transplantation
    Patent number: 10940189
    Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 9, 2021
    Assignee: CYTONICS CORPORATION
    Inventors: Lewis Hanna, John David Laughlin, Shawn Robert Browning
  • Compositions and methods for cartilage repair
    Patent number: 10898497
    Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: January 26, 2021
    Assignee: REGENEXX, LLC
    Inventor: Christopher J. Centeno
  • Nucleic acid molecules encoding for chimeric CSPG4 proteins and therapeutic uses thereof
    Patent number: 10849967
    Abstract: A nucleic acid molecule encoding a chimeric chondroitin sulfate proteoglycan 4 (CSPG4) protein, wherein the chimeric CSPG4 protein comprises, from the N-terminal to the C-terminal: i) a first portion derived from the human CSPG4 sequence and a second portion derived from the canine CSPG4 sequence or ii) a first portion derived from the canine CSPG4 sequence and a second portion derived from the human CSPG4 sequence.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: December 1, 2020
    Assignee: Università degli Studi di Torino
    Inventors: Federica Cavallo, Paolo Buracco, Federica Riccardo, Maddalena Arigoni, Elena Quaglino, Raffaele Adolfo Calogero, Soldano Ferrone
  • Bone-targeting antibodies
    Patent number: 10844115
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • Ophthalmic compositions and methods of use therefor
    Patent number: 10842850
    Abstract: The present invention encompasses ophthalmic compositions that may be used for various conditions of the eye, and particularly, conditions of the cornea. Also encompassed are methods that utilise these compositions and kits that include these compositions.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: November 24, 2020
    Inventors: Colin Green, Carol Ann Greene, Trevor Sherwin
  • Method for treating or/and preventing calcium deficiency-related diseases
    Patent number: 10829517
    Abstract: The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 10, 2020
    Assignee: NATIONAL CHUNG HSING UNIVERSITY
    Inventors: Chuan-Mu Chen, Hsiao-Ling Chen
  • Bone repair product and methods of use thereof
    Patent number: 10828395
    Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: November 10, 2020
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Thomas E. Uveges, Jin-Qiang Kuang, Alla Danilkovitch, S. Michael Sinclair, Sandra D. Geraghty
  • Method for preparing antibody through regulation of sugar content of antibody
    Patent number: 10808272
    Abstract: Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content. Furthermore, provided is a medium composition, for regulating the antibody sugar chain content, the medium composition including glycerol as an additive for regulating the antibody sugar chain content.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: October 20, 2020
    Assignee: Prestige Biopharma PTE. LTD.
    Inventors: Jae Young Chang, Eun Ho Hwang, Yong Jin Kim, Won Kyum Kim, Sang Kyung Park, Jun Yong Park, Kyo Eun Ahn, Yong Ho Ahn, Ji Yong Yoon, Jung Woo Lee
  • Treatment for bone diseases
    Patent number: 10799583
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 13, 2020
    Assignee: UCB PHARMA, S.A.
    Inventor: Martyn K. Robinson
  • Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
    Patent number: 10787494
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mary Struthers, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • Methods of reducing aggregation of IL-1ra
    Patent number: 10765747
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 8, 2020
    Assignee: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Andrei Raibekas, Bruce Kerwin
  • Methods and compositions for regenerating tissues
    Patent number: 10752663
    Abstract: Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: August 25, 2020
    Assignee: NELLONE THERAPEUTICS, INC.
    Inventor: Cymbeline T. Culiat
  • Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
    Patent number: 10745475
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: August 18, 2020
    Assignee: TAKEDA GMBH
    Inventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft